Preventing Angiographic Progression of Coronary Atherosclerosis with Pravastatin

We conducted a prospective study to investigate the relationship between the decrease of serum lipid levels during pravastatin therapy and changes of coronary angiography parameters in Japanese patients with coronary atherosclerosis. The patients were predominantly male, aged between 18 and 75 years...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Atherosclerosis and Thrombosis 2003, Vol.10(1), pp.25-31
Main Authors: Daida, Hiroyuki, Ouchi, Yasuyoshi, Saito, Yasushi, Yamada, Nobuhiro, Nishide, Toshio, Mokuno, Hiroshi, Kurata, Takeshi, Sato, Hitoshi, Eto, Masato, Ako, Jun-ya, Tango, Toshiro, Yamaguchi, Hiroshi
Format: Article
Language:English
Subjects:
Coronary Angiography
Coronary Artery Disease - blood
Coronary Artery Disease - diagnostic imaging
Coronary Artery Disease - prevention & control
Coronary Vessels - pathology
Disease Progression
Endpoint Determination
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Lipids - blood
Male
Middle Aged
Percent reduction of serum cholesterol
Pravastatin
Pravastatin - therapeutic use
Prospective Studies
Prospective study
Quantitative coronary angiography
Regression Analysis
Risk Factors
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We conducted a prospective study to investigate the relationship between the decrease of serum lipid levels during pravastatin therapy and changes of coronary angiography parameters in Japanese patients with coronary atherosclerosis. The patients were predominantly male, aged between 18 and 75 years (mean: 58 years), had at least 25% stenosis of one or more major coronary arteries, and had a serum total cholesterol ( TC) level ≥ 200 mg/dl (5.18 mM/l). Treatment with pravastatin (10 mg/day) was continued for 3 years. Coronary angiography was performed before and 3 years after the start of pravastatin therapy to assess the relationship between the mean segment diameter (MSD), the minimal lumen diameter (MLD), and the annual changes of percent stenosis and TC levels. of 265 patients who were initially registered, 129 were followed for an average of 35 months. Consequently, second angiograms were only obtained in 68 patients for various reasons, so this group was used for analysis. During pravastatin therapy, the TC level significantly decreased from 239 mg/dl (6.19 mM/l) to 210 mg/dl (5.44 mM/l) (a 12% reduction; p
ISSN:1340-3478
1880-3873
DOI:10.5551/jat.10.25